A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Inclusion Criteria: * Are 18 to 80 years old (including boundary values), without limitation of sex at time of consent. * Based on the RECIST 1.1 criteria for disease progression, (a maximum increase in tumour diameter of 20%) for participants undergoing prescreening who are receiving standard treatment, these participants may reach the defined disease progression criteria at the time of tumour vaccine administration. Exclusion Criteria: * Have used a live attenuated vaccine within 4 weeks before the first use of SW1115C3 with the following exceptions: * Adverse reactions induced by previous anti-tumour treatments have not yet recovered to Grade ≤ 1 (except for toxicity evaluated to have no risk of safety by the PI \[or designee\], such as hair loss, Grade 2 peripheral neurotoxicity and hypothyroidism stabilised by hormone-replacement therapy) based on NCI CTCAE version 5.0.